Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).
about
An update on the role of testosterone replacement therapy in the management of hypogonadismTestosterone deficiency in the aging maleThe treatment of late-onset hypogonadismMetabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsOutcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinologyThe effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trialsTestosterone and the cardiovascular system: a comprehensive review of the clinical literatureSex hormones in the cardiovascular systemAndrogen deficiency and metabolic syndrome in menEndogenous sex hormones, metabolic syndrome, and diabetes in men and womenTestosterone and vascular function in agingThe paradox of progress: environmental disruption of metabolism and the diabetes epidemicSex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes MellitusTransversal European survey on testosterone deficiency diagnosis.Carotid artery intima-media thickness and erectile dysfunction in patients with metabolic syndromeMen with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.The relationship between sex hormones, sex hormone binding globulin and peripheral artery disease in older personsBaseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency.Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).Testosterone deficiency and replacement: Myths and realities.Testosterone and weight loss: the evidence.An update on male hypogonadism therapy.Single-nucleotide polymorphism, rs1799941 in the Sex Hormone-Binding Globulin (SHBG) gene, related to both serum testosterone and SHBG levels and the risk of myocardial infarction, type 2 diabetes, cancer and mortality in men: the Tromsø Study.Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications.Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes.Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.Testosterone deficiency and cardiovascular mortality.Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome.Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetesTestosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence.Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesitySex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart studyTestosterone replacement and cardiovascular safety: no straight and narrow!The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.Acute testosterone deprivation reduces insulin sensitivity in menLow concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus.Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review.Connecting the Lines between Hypogonadism and Atherosclerosis.
P2860
Q26749076-DCB5B52F-5FA9-4076-A434-C42898AEB3B7Q26770414-6376E379-ABFA-44B3-81F4-85EEABE20000Q26795519-1F32B490-CF0B-4A1A-AB6D-856B0D718BE5Q26822761-F75DECA0-9399-4532-B05E-694FA79BEFDBQ26864777-D3A40A2D-7088-45B2-B27D-1B5854A24AC0Q26999003-7F1F0BF7-3CF1-4570-ADFA-223E81C8CFF4Q27000507-3B09A08F-BD52-47BB-A533-BC4386FD0544Q27013717-CCEBC7AF-4B15-491D-B402-6D0BD1E4A326Q27013723-47DD3FEF-8534-4AA7-AFD3-B6C856C32516Q27023901-2F311EF8-D44F-4D66-B683-62E87C28435CQ28383213-F1A4E128-98FD-4B3A-BFA1-683E2231CE17Q28389669-F5982DC6-7C7F-4365-B1F3-CD9843EC8479Q28395801-8329355D-C94E-4C18-93EC-6B3C537614CAQ30318156-5B78F124-2E5E-45A9-AE3A-8AE7C8EA23EFQ30362959-F823F5D9-9243-45DA-B91C-0977BB3E307DQ31111735-BB641D5D-4BF5-450E-A021-5C94F0F1C459Q33729775-57F6F923-2B33-4360-B64A-CEFC5D21E708Q33897720-F4A12B3C-7A48-4AA4-BC1A-1B476A003BA7Q34063853-0EF84067-2E59-4238-B0AA-FC43F4BAC46DQ34093530-84A5BCF4-1B4C-4220-BA2D-61FDB7AC1C53Q34134273-73F2B7AC-E49A-46C0-9DE1-E26B388848EAQ34207540-0C6C272A-3282-4FA4-A964-06F60FF15C6CQ34391105-995475AC-5225-423F-BB49-48D6D2229F87Q34398768-DE2B0DA2-5ACC-43D7-8C9F-E6A88065F3FDQ34578805-2915042F-921B-496B-B701-46449B89349BQ34628361-0D7D076E-B887-488A-80F9-E6D52BBD030AQ34676945-C9084A3C-1921-4724-9D44-1B2AD700C6DCQ34804834-85D13E1D-6029-46A8-AAEE-2AF74DDE3F4FQ34927884-0A931843-B453-4F14-A836-B6E267B22998Q34999016-909C07D5-6FE3-4266-BFE7-FE45F8F615C4Q35060256-0861B86C-EDBE-4A71-89E7-6240AE5539DCQ35192163-9F07E946-D349-4029-877D-4768E0773A36Q35198511-AFEDEBCD-54A2-4459-980F-0193B8C3AC3CQ35408545-139B5AAB-FA7D-4A30-B6DF-AE23830D1A32Q35546614-3F820C81-A088-4D94-98E0-F3A2C9ED0282Q35549154-5D27D2A3-6B83-4D72-9633-0E337E2E7EB3Q35573457-A79E8303-4AF9-485D-8572-FA9728BD2E33Q35713227-8DC8DD41-E3E0-4B4F-94F8-1502FE046AEDQ35810322-26CCC5DE-52F0-47E9-BB50-FA44E2D3C3EEQ35810628-373D2739-43BD-47D3-B367-DEA8926406F3
P2860
Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Testosterone replacement in hy ...... c syndrome (the TIMES2 study).
@ast
Testosterone replacement in hy ...... c syndrome (the TIMES2 study).
@en
Testosterone replacement in hy ...... etes and/or metabolic syndrome
@nl
type
label
Testosterone replacement in hy ...... c syndrome (the TIMES2 study).
@ast
Testosterone replacement in hy ...... c syndrome (the TIMES2 study).
@en
Testosterone replacement in hy ...... etes and/or metabolic syndrome
@nl
prefLabel
Testosterone replacement in hy ...... c syndrome (the TIMES2 study).
@ast
Testosterone replacement in hy ...... c syndrome (the TIMES2 study).
@en
Testosterone replacement in hy ...... etes and/or metabolic syndrome
@nl
P2093
P2860
P356
P1433
P1476
Testosterone replacement in hy ...... ic syndrome (the TIMES2 study)
@en
P2093
Ann Yellowlees
Antonio Martin Morales
Eric Meuleman
Hermann M Behre
Ignacio Moncada
Jacques Buvat
Julian D Howell
Kevin S Channer
T Hugh Jones
TIMES2 Investigators
P2860
P304
P356
10.2337/DC10-1233
P407
P577
2011-03-08T00:00:00Z